A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYMAKER-U02): Substudy 02C

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506314-51-00

Acronym

MK-3475-02C

Enrollment

Registered

2024-02-14

Start date

2020-07-31

Completion date

2025-09-09

Last updated

2025-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stage IIIB or IIIC or IIID melanoma

Brief summary

Percentage of participants who experience an adverse event (AE), Percentage of participants who discontinue study treatment due to an AE, Pathological complete response (pCR) rate

Detailed description

Near pathological complete response (near pCR) rate, Pathological partial response (pPR) rate, Recurrence-free survival (RFS)

Interventions

DRUGTRETINOIN

DRUGgebasaxturev

DRUGMK-4280A

DRUGvibostolimab

DRUGMK-4830

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percentage of participants who experience an adverse event (AE), Percentage of participants who discontinue study treatment due to an AE, Pathological complete response (pCR) rate	—

Secondary

Measure	Time frame
Near pathological complete response (near pCR) rate, Pathological partial response (pPR) rate, Recurrence-free survival (RFS)	—

Countries

France, Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026